

March 1, 2013

Announcements

North Haven Medical Center Opens

Yale-New Haven Hospital officially opened their new North Haven Medical Center yesterday. As part of the new facility, a new Smilow Cancer Care Center opened, and the medical oncologists from the Care Center in Hamden have relocated to North Haven. Drs. Thomas Fynan, Martin Katz, Jeremy Kortmansky, and Kathleen Bober-Sorcinelli are now seeing their patients in the new facility in North Haven. In addition to the Cancer Care Center, the medical center also includes a Walk-in Care Center, Interventional Immunology Center, Diagnostic Radiology Services, and Laboratory and Blood Draw Services. Appointments can be made at the North Haven Smilow Cancer Care Center by calling (203) 407-8002.



[Watch Video of Ribbon-Cutting Event >>](#)

Yale Urology Welcomes Two New Faculty Members

Peter Schulam, MD, PhD, Chief of Urology, Clinical Program Leader of the Prostate and Urologic Cancers Program at Smilow Cancer Hospital, and Assistant Director for Surgery for Yale Cancer Center, has appointed Simon Kim, MD, MPH and Brian Shuch, MD as Assistant Professors in the Department of Urology. Their tenure will begin on July 1.

from the desk of

Thomas J. Lynch, Jr., MD

Director, Yale Cancer Center

Physician-in-Chief Smilow Cancer

Hospital at Yale-New Haven



Join Yale Cancer Center on Facebook

Like us on Facebook 

Closer to Free

give
closer to free

Help advance cancer research and enhance patient care.

Links of Interest

CV Library

The CV library is a new resource available to our members, with CVs of post-docs and others looking for positions at Yale. Please browse the listings if you have openings, and send the



Dr. Kim will join Yale from the Mayo Clinic where he will complete his urologic oncology fellowship in June. He received his MPH and his MD from the University of Chicago and completed his urology residency and surgical internship at the University of Michigan. Dr. Kim will care for patients with bladder, kidney, and prostate cancer through the Prostate and Urologic

Cancers Program at Smilow Cancer Hospital and at the West Haven VA. His research focus is on health services research in improving the delivery of healthcare and outcomes for patients diagnosed with genitourinary malignancies. Dr. Kim will be part of the Yale COPPER Program, under the direction of Drs. Cary Gross and Xiaomei Ma.



Dr. Shuch is completing a urologic oncology fellowship at the National Cancer Institute. He is a graduate of the University of Michigan and received his MD from New York University before completing his urology residency and surgery internship at the University of California - Los Angeles. Dr. Shuch's clinical interest is in the multidisciplinary management of sporadic and hereditary

forms of kidney cancer. He will work with the Yale Cancer Center Genetic Counseling Office to care for high-risk renal cell carcinoma (RCC) patients. In addition, he will be working with Drs. Harriet Kluger and Mario Sznol on the development of a multidisciplinary RCC program to develop novel therapies and to offer neoadjuvant and adjuvant clinical trials for patients with RCC.

Clinical and Translational Research Methods in Oncology Workshop

Please join us on Saturday, April 13 from 8 AM - 4 PM in the auditorium at 55 Park Street for a workshop in the methods of clinical trial design and protocol development with a focus on cancer therapy. The goal of the workshop is to introduce residents, fellows, research personnel and faculty interested in clinical research to the principles of clinical trial design and provide them with the information and tools they need to conduct clinical trials and design investigator-initiated trials. Lectures and panel discussions will provide an overview of the principles of design and conduct of Phase I and II clinical trials and will address translational correlates, imaging endpoints as well as quality of life assessments. Fellows will be given the opportunity to submit a letter of intent for investigator-initiated

CVs you receive to share.
[Learn More >>](#)

In the News

Read recent articles featuring experts from Yale Cancer Center.

[Read More >>](#)

Subscribe to Yale Cancer Center Answers on iTunes

Yale Cancer Center's weekly radio program on CT Public Radio is ranked number 2 in the world for cancer programs on iTunes. Subscribe to the show.

[Learn More >>](#)

Yale Cancer Center Grand Rounds

Video presentations from Yale Cancer Center members are now available online.

[Learn More >>](#)

DirectConnect Archives

[Learn More >>](#)

Events

March 1; 12:00 PM YCC Research in Progress Meeting

WWW 208

Approaches to the Treatment of Castration Resistant Prostate Cancer

Daniel Petrylak, MD

[Learn More >> \(PDF\)](#)

March 1; 12:00 PM Yale Center for Clinical Investigation

TAC N-107

All Scholar Day Retreat

[Learn More >> \(PDF\)](#)

March 1; 3:00 PM YCC Special Seminar

WWW 208

Combining Vaccine with Hormonal Therapy for Prostate Cancer

Joseph Kim, MD

[Learn More >> \(PDF\)](#)

March 3; 6:00 PM Yale Cancer Center Answers

WNPR

Colorectal Cancer

trials, and 2 concepts will be selected for discussion at the end of the workshop. A certificate of workshop completion will be provided for residents and fellows in training.

Topics/Speakers:

Design and analysis of Phase I Trials: *Paul Eder*

Clinical pharmacology: PK/PD endpoints: *Paul Eder*

Phase II Trial: Clinical endpoints/novel designs: *Mario Sznol*

Phase II Trial: Statistical design and analysis: *Xiaopan Yao*

Translational/correlative studies in clinical trials: *Lajos Pusztai*

Radiology: RECIST and imaging endpoints in clinical trials: *Jay Pahade*

Investigator-initiated clinical trials: *Maysa Abu-Khalaf & Rebecca Lilian*

Quality of life and survivorship endpoints: *Tara Sanft & Tish Knobf*

PCOR in oncology: *Cary Gross*

Informed consent and ethical consideration in Oncology: *Kathleen Uscinski*

Course Co-Directors:

Maysa Abu-Khalaf

Jill Lacy

Please RSVP by March 22, 2013 to [Tracy Chidsey](#).

Notables

Renowned Yale immunologist **Ruslan Medzhitov** has been awarded the inaugural Lurie Prize in the Biomedical Sciences from the Foundation for the National Institutes of Health (FNIH). The award, which honors early-career researchers whose findings have advanced basic biomedical science, was given to Medzhitov for his groundbreaking discoveries about the workings of the innate immune system, the body's first line of defense against bacteria and viruses.

Medzhitov was nominated for the Lurie award by his Yale colleague Richard Flavell, Sterling Professor of Immunobiology, chairman of the department, and also a

Awareness Month
Howard Hochster, MD and
Harry Aslanian, MD
[Learn More >>](#)

March 5; 12:00 PM
Yale Cancer Center
Grand Rounds
Park Street Auditorium
Advances in Breast Cancer Risk Assessment, Genetic Testing, and Management
Banu Arun, MD
[Learn More >> \(PDF\)](#)

March 5; 4:30 PM
Yale Cancer Center Evening
Oncology Series
North Pavilion Room 4-101
A & B
Breast Cancer and BRCA Positive Patients
[Learn More >>](#)

March 5; 5:30 PM
Yale Lung Screening
and Nodule Program
Park Street Auditorium
Lung Cancer Screening
[Learn More >>](#)

March 8; 12:00 PM
YCC Research in
Progress Meeting
WWW 208
Lung Carcinogenesis: Discovering Novel Molecular Targets for Cancer Therapy and Prevention
J. Peter Koo, PhD
[Learn More >> \(PDF\)](#)

March 8; 2:00 PM
YCC Hematology
Special Seminar
WWW 208
Update on Iron Overload and its Management
Kanwarpal Kahlon, MD
[Learn More >> \(PDF\)](#)

March 10; 6:00 PM
Yale Cancer Center Answers
WNPR
Update on Cardiac Side Effects of Chemotherapy
Kerry Russell, MD, PhD,
FACC, FAHA
[Learn More >>](#)

March 12; 12:00 PM
Yale Cancer Center
Grand Rounds

Howard Hughes Medical Institute investigator.

Medzhitov, a member of Yale Cancer Center, was one of three scientists awarded the prestigious Shaw Prize in Life Science and Medicine for 2011. In April, 2010, he received one of the highest honors bestowed on American scientists when he was elected to the National Academy of Sciences, the elite corps of researchers from the nation's top scientific institutions.

[Read More >>](#)

Hilary Prosnitz has been named Chief of Staff for the Yale Cancer Center Director's Office. Most recently, Hilary was a program coordinator in Yale Cancer Center's research affairs office where she helped with the writing, coordination, and submission of the Cancer Center Support Grant to the NCI. In Hilary's new role she will oversee special projects and strategically important initiatives at the discretion of the Yale Cancer Center leadership.

Closer to Free

Closer to Free Ride Kicks Off

Please join us as we officially launch the **2013 Closer to Free Ride** at our fabulous kickoff event!



Join us for refreshments and an opportunity to meet the Ride community. Online registration will be available at the party, and if you register as a rider or volunteer at the event you'll get a special gift! All are welcome to attend so spread the word, bring your friends and get excited for this year's Ride!

[RSVP Today.](#)

When:

Park Street Auditorium
Tanning Addiction, Indoor Tanning, and Skin Cancer
Brenda Cartmel, MD

Cancer and Contraception
Aileen M. Gariepy, MD, MPH
[Learn More >> \(PDF\)](#)

March 14; 9:00 AM Therapeutic Radiology Grand Rounds

Smilow, Lower Level, Room E
Molecular Imaging in Radiation Oncology: Opportunities and Challenges
Edward E. Graves, PhD
[Learn More >>](#)

March 14; 10:00 AM Office of Research Compliance and Education Training Programs

47 College St
Direct Charging of F&A Type Costs to Sponsored Awards
[Learn More >>](#)

March 15; 7:30 AM Continuing Medical Education/Neurosurgery Seminar

Jane Ellen Hope Building
The Evolution of Multidisciplinary Management of Brain Metastases
[Learn More >>](#)

March 15; 12:00 PM YCC Research in Progress Meeting

WWW 208
neXt drug discovery and initiatives in sarcoma and small cell lung cancer
Beverly Teicher, PhD
[Learn More >> \(PDF\)](#)

Employment Opportunities

We seek your assistance in the recruitment of qualified Oncology Research Nurses to join the Cancer Center for full time research opportunities. Positions traditionally require a minimum of BSN and 4 years of research nursing experience with a strong preference within oncology. In lieu of research

Thursday, April 4
5:00 pm - 7:00 pm

Where:

The Study at Yale
1157 Chapel Street

Yale Basketball Supports Closer to Free

Due to the recent snow storm, the Yale Women's Basketball annual fundraising event to benefit the Closer to Free Fund and support YCC breast cancer research and the SCH Breast Center has been rescheduled for Friday and Saturday, March 1 and 2. Tonight, the team plays Columbia at 7PM at Payne Whitney Gym. On Saturday, both men and women teams of three can register to participate in the **Battle of the Badges**, a bench-press competition. Saturday evening, the team plays Cornell at 7PM. The proceeds from a game-time raffle, silent auction, and the sale of specially designed t-shirts all support **Closer to Free**. Visit yalebulldogs.com/pinkzones or contact [Susan Frankenbach](#) for more information.

Development Update

For the third year in a row, **BJ's Charitable Foundation** has awarded Yale Cancer Center with a grant to support breast cancer research and treatment. Over \$100,000 has been donated to-date. The grant comes from the proceeds of specially packaged Proctor & Gamble products sold at BJ's Wholesale Clubs during the month of October throughout the New England and Mid-Atlantic area. These "Pink Ribbon" club products support the BJ's Charitable Foundation, which annually distributes the proceeds to fourteen NCI-designated cancer centers in the BJ's sales region, including Yale Cancer Center.

Lung Screening Education

The Yale Lung Screening and Nodule Program (Yale Lung SCAN) will be hosting an educational evening event on March 5th from 5:30-8PM in the Smilow Auditorium, at 55 Park Street in New Haven to explore the current state of lung cancer screening. The purpose of the evening is to share what Yale Lung SCAN has learned in the process of setting up their program and discuss how best to partner with their colleagues.

Screening for lung has become a topic of great interest since

experience, trained oncology nurses with little or no research experience are considered for positions of the same level. Should you know of any potential candidates, please encourage them to go on-line to www.yale.edu/jobs and navigate to the STARS employment website in search of positions 18343BR and 18943BR, upload the resume and apply. They may also contact [Sandra Greer](#) for further information.

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

renee.gaudette@yale.edu

 Forward to a Friend

the official release of the results of the National Lung Screening Trial (NLST) in mid 2011. The NLST provided us with good evidence that lung screening with low dose computed tomography in a specific population decreases the mortality rate from lung cancer by 20%. However, it is clear that lung cancer screening is a complex process, involving risk assessment, acknowledgement of the potential harms of screening, and necessitating appropriate management of the inevitable large number of false positive results requiring judicious evaluation and intervention. Because lung screening is new, details are still evolving with many questions still unanswered. All society guidelines call for screening to be done in the context of a structured comprehensive program.

The Yale Thoracic Oncology Program team has spent a year developing our screening program, which was recently selected by the American College of Chest Physicians as a "Center of Excellence" model for lung cancer screening.

The Yale Lung Screening and Nodule Program (Yale Lung SCAN) welcomes your participation in this educational event. Please RSVP to [Amanda Reid](#).

Employee Profile: Danielle Wanik

The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being done here, and the dedication and values we possess. To suggest someone to be profiled, please contact [Emily Fenton](#).

One of the most important aspects of Danielle Wanik's job as Clinical Trials Assistant for Thoracic Oncology in the Clinical Trials Office is making sure patients follow the protocols as they are written by the sponsor to ensure they are treated safely. She spends most of her time monitoring patients on the clinical trials, and working with thoracic oncology physicians and APRNs, clinical research nurses, and the



clinical research support lab.

Danielle is responsible for coordinating all of the labs, physicals, chemotherapy infusions, imaging, ophthalmology, and cardiology appointments that patients require while on a trial, within a specific timeline. She has been in her current position for a year and a half, after receiving her B.S. in Health Management and Policy, and completing an internship at a cancer genetics clinic, which is where her interest in oncology came from.

"It can be challenging to work with very sick patients, but it is also very rewarding. I am an optimistic person and find my job to be very fulfilling," said Danielle.

Danielle specializes in anti-PD-1 trials and the BATTLE-2 trial. The principle of anti-PD1 therapy was discovered in Dr. Lieping Chen's laboratory. Anti-PD1 has been found to be very effective in treating patients with lung cancer. BATTLE-2 is a trial that aims to identify new targets and rational combinations of molecularly targeted therapies that will lessen the effects of mutant KRAS in patients with non-small cell lung cancer.

Kathleen Uscinski, Associate Director for Clinical Trials Operations, commented, "Danielle has many demands on her time. It is very common to encounter roadblocks while assisting patients, physicians, and research nurses with the endless demands of running clinical trials. Yet, Danielle accomplishes her goals and does so with an upbeat, can-do attitude that is infectious and hugely appreciated. I think Danielle epitomizes the perfect YCC employee. She accomplishes the busy and complicated tasks in a confident and delightful manner that ensures our cancer patients get access to top notch clinical trials in a high quality environment."

Funding Opportunities

Yale Cancer Center Translational-Targeted Area of Research Excellence (T-TARE) Awards

These grants will support research with a significant translational potential/clinical component for groups of between three and five investigators headed by a member of the Cancer Center. The major review criteria for this award are translational potential, scientific excellence, and the likelihood that the proposed program will result in submission of multi-investigator grant applications, such as a P01 or P50 application, at the conclusion of the T-TARE funding.

Award Amounts: Up to \$200,000 for one year commencing July 1, 2013.

Purpose: To provide seed money to members of the Yale

Comprehensive Cancer Center to support studies on the same general topic with a significant translational research component by three or more faculty members, to generate preliminary data or evidence of collaboration for a new, multi-investigator grant application to the National Cancer Institute, such as a Program Project grant or SPORE grant.

Eligibility: Members of the YCCC or faculty who have applied for membership are eligible to serve as P.I. Each application shall include between three and five projects led by different faculty members. In addition to the P.I. and project leaders, each project should include collaboration with a biostatistician and allocate a portion of the budgeted funds to support this effort.

Application Deadline: April 26, 2013

[Learn More and Download Applications >>](#)

Recent Publications

Absence of aneuploidy and gastrointestinal tumours in a man with a chromosomal 2q13 deletion and BUB1 monoallelic deficiency.

Hoang D, Sue GR, Xu F, Li P, Narayan D.
BMJ Case Rep. 2013 Feb 25;2013.

[Read More >>](#)

Assessing and managing metabolic syndrome and cardiovascular risk in midlife women.

Coviello JS, Knobf MT, Laclergue S.
J Cardiovasc Nurs. 2013 Mar;28(2):147-56.

[Read More >>](#)

HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy?

Hochster HS.
Br J Cancer. 2013 Feb 19;108(3):477-8.

[Read More >>](#)

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberger D, Brown JR, Getz G, Wu CJ.

Cell. 2013 Feb 14;152(4):714-26

[Read More >>](#)

Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High-throughput Screen.

Sayegh J, Cao J, Zou MR, Morales A, Blair LP, Norcia M,

Hoyer D, Tackett AJ, Merkel JS, Yan Q.
J Biol Chem. 2013 Feb 13.

[Read More >>](#)

Prostate cancer: Interpreting cost-utility analysis of prostate cancer treatment.

Yu JB.
Nat Rev Urol. 2013 Feb 12.

[Read More >>](#)

The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China.

Bai M, Reynolds NR, McCorkle R.
Palliat Support Care. 2013 Feb 11:1-20.

[Read More >>](#)

Disparities in stage at diagnosis among adults with testicular germ cell tumors in the National Cancer Data Base.

Lerro CC, Robbins AS, Fedewa SA, Ward EM.
Urol Oncol. 2013 Feb 7.

[Read More >>](#)

Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.

Zhu R, Baumann RP, Patridge E, Penketh PG, Shyam K, Ishiguro K, Sartorelli AC.
Bioorg Med Chem Lett. 2013 Jan 11.

[Read More >>](#)

Fenbendazole as a potential anticancer drug.

Duan Q, Liu Y, Rockwell S.
Anticancer Res. 2013 Feb;33(2):355-62.

[Read More >>](#)

Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction.

Kwak M, Mu L, Lu Y, Chen JJ, Brower K, Fan R.
Front Oncol. 2013;3:10.

[Read More >>](#)

Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.

Leonhardt RM, Vigneron N, Hee JS, Graham M, Cresswell P.
Mol Biol Cell. 2013 Feb 6.

[Read More >>](#)

Adaptive resistance: a tumor strategy to evade immune attack.

Yao S, Chen L.
Eur J Immunol. 2013 Feb 4.

[Read More >>](#)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.

Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM.

BMC Clin Pathol. 2013 Feb 1;13(1):3.

[Read More >>](#)

Functional Impairments as Symptoms in the Symptom Cluster Analysis of Patients Newly Diagnosed With Advanced Cancer.

Fodeh SJ, Lazenby M, Bai M, Ercolano E, Murphy T, McCorkle R.

J Pain Symptom Manage. 2013 Feb 1.

[Read More >>](#)